Skip to main content
SpringerLink
Log in

Incidence of Inhibitor Development in consecutively recruited severe Hemophilia A and B Patients — a retrospective Single Centre Study

  • Conference paper
32nd Hemophilia Symposium

  • 103 Accesses

Abstract

Hemophilia A (HA) and B (HB) are X-linked genetic disorders resulting in deficiencies of blood coagulation factors VIII and IX. In order to prevent joint bleedings and hemophilic arthropathy in hemophilia patients, a long-term prophylactic therapy with factor VIII or IX concentrates has been suggested. This coagulation factor substitution can be complicated by the development of antibodies against factor VIII or IX (sc. inhibitors).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anson DS, unno KH, Rees DJG, Gianelli F, Gould K, Huddieston JA, Brownlee GG (1984) The gene structure of human anti-hemophilic factor IX. The ENBO Journal 3, 1053–1060

    CAS  Google Scholar 

  2. Biggs R: Jaundice and antibodies directed against factors VIII and IX in patients treated for hemophilia or Christmas disease in the United Kindom. Br J Haematol 1974, 26(3): 313–29

    Article  PubMed  CAS  Google Scholar 

  3. Bogdanova N, Markoff M, Pollmann H, Nowak-Göttl U, Eisert R, Dworniczak B, Eigel A, Horst J (2002) Prevalence of SMall Rearrangements in the Factor VIII Gene AMong Patients with Severe Hemophilia A. Hum Mutat, in press

    Google Scholar 

  4. Briet E, Rosendaal FR, Kreuz W, et al: High titer inhibitors in severe hemophilia A. A Metaanalysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb and Haemost 1994, 72(1): 162–164

    CAS  Google Scholar 

  5. Briet E, Rosendaal FR: Inhibitors in hemophilia A: are some products safer? Semin Hematol 1994,31: 11–15

    PubMed  CAS  Google Scholar 

  6. Carol KK: A More uniform Measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975, 34: 869

    Google Scholar 

  7. Ehrenforth S, Kreuz W, Scharrer I, et al: Incidence of development of factor VIII and IX inhibitors in hemophiliacs. Lancet 1992,339(8793): 594–598.

    Article  PubMed  CAS  Google Scholar 

  8. Gianelli F, Anson DS, unno KH, Rees DJG, Winship PR, Ferrari N, Rizza CR, Brownlee GG (1984) Characterization and use of an intragenic polymorphic Marker for detection of carriers of hemophilia B (factor IX deficiency). Lancet, i, 239–241

    Article  Google Scholar 

  9. Gilles JG, Jacquemin MG, Saint-Remy JM, et al: Factor VIII inhibitors. Thromb Haemost 1997,78(1): 641–646

    PubMed  CAS  Google Scholar 

  10. Goodeve AC, Williams I, Bray GL, et al: Relationship between factor VIII Mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost 20000, 83(6): 844–848

    Google Scholar 

  11. Hoyer LW: Why do so Many hemophilia A patients develop an inhibitor? Br J Haematol 1995,90(3): 498–501

    Article  PubMed  CAS  Google Scholar 

  12. Kavakli K, Gringeri A, Bader R, et al: Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia 1998,4: 104–108

    Article  PubMed  CAS  Google Scholar 

  13. Knobe KE, Villoutreix BO, Tengborn LI, et al: Factor VIII inhibitors in two families with Mild hemophilia A: structural analysis of the Mutations. Haemostasis 2000,30(5): 268–279

    PubMed  CAS  Google Scholar 

  14. Koeberl DD, Bottema CDK, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS (1990) Mutations causing hemophilia B: direct estimate of the underlying rates of spontaneous germ-line transitions, transversions and deletions in the human gene. AM J Hum Genet 47:202–217

    PubMed  CAS  Google Scholar 

  15. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, et al: Epidemiology of inhibitors in hemophilia A. Vox Sang 1996,70(1): 2–8

    Article  PubMed  Google Scholar 

  16. Kreuz W, Auerswald G, Budde U, et al: Inhibitor incidence in previously untreated patients (PUPs) with hemophilia A and B — A prospective, Multicenter study of the pediatric study group of the German, Swiss and Austrian Society of Thrombosis and Hemostasis (GTH). Blood 2001, ASH 2238 (abstract)

    Google Scholar 

  17. Lakich D, Kazaziean HH, Antonarakis SE, Gischier: Inversions disrupting the factor VIII gene as a common cause of severe hemophilia A. Nature Genet. 1993, 5:236–241

    Article  PubMed  CAS  Google Scholar 

  18. Manco-Johnson MJ, Nuss R, Funk S, et al: Joint evaluation instruments for children and adults with hemophilia. Haemophilia 2000,6: 649–657

    Article  PubMed  CAS  Google Scholar 

  19. Miller SA., Dykes DD, Polesky HF: A simple salting procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215

    Article  PubMed  CAS  Google Scholar 

  20. Rasi V, Ikkala E, et al: Hemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990,76(3): 369–71

    Article  PubMed  CAS  Google Scholar 

  21. Oldenburg J, El-Maarri O, Schwaab R: Inhibitor development inhibitor correlation to factor VIII genotypes. Haemophilia 2002,8: 23–29

    Article  PubMed  CAS  Google Scholar 

  22. Pollmann H, Richter H, Ringkamp H, JÜrgens H: When are children diagnosed as having severe hemophilia and when do they start to bleed? A 10-year single center PUP study. Eur J Paediatr 1999; 158(Suppl 3): 166–170

    Article  Google Scholar 

  23. Salviato R, Belvini D, Are A, et al: Large FVIII gene deletion confers very high risk of inhibitor development in three related severe hemophiliacs. Haemophilia 2002,8(1): 17–21

    Article  PubMed  CAS  Google Scholar 

  24. Scharrer I, Bray GL, Neutzling O: Incidence of inhibitors in hemophilia A patients — a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999,5(3): 145–154

    Article  PubMed  CAS  Google Scholar 

  25. Scharrer I, Neutzling O: Incidence of inhibitors in hemophiliacs. A review of the literature. Blood Coagul and Fibrinolysis 1993,4(5): 753–758

    CAS  Google Scholar 

  26. Scharrer I, Neutzling O, Schwaab R, et al: Experiences with recombinant factor VIII products: development of inhibitor and immune tolerance therapy. Ann of Hematol 1998,76. A1–A6

    Article  Google Scholar 

  27. Schwaab R., Oldenburg J., Lalloz M.R., Schwaab U., Pemberton S., Hanfland P., Brackmann H.H., Tuddenha M E.G., Michaelides K. Factor VIII gene Mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a Molecular Model of factor VIII protein. Hum Genet 1997,101(3):323–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. Halimeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Kosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Bogdanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Abshagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Jürgens
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hemophilia Center, Dept. of Internal Medicine, University Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    Inge Scharrer

  2. Dept. of Hemostasiology, University Hospital, Ziemssenstr. 1a, D-80336, München, Germany

    Wolfgang Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Halimeh, S., Kosch, A., Bogdanova, N., Abshagen, K., Jürgens, H. (2003). Incidence of Inhibitor Development in consecutively recruited severe Hemophilia A and B Patients — a retrospective Single Centre Study. In: Scharrer, I., Schramm, W. (eds) 32nd Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18150-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18150-4_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-43884-7

  • Online ISBN: 978-3-642-18150-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation